Ceftolozane Susceptibility Testing 

Ceftolozane-tazobactam is a combination of a novel cephalosporin (ceftolozane) with a beta-lactamase inhibitor (tazobactam). This combination is designed to treat Gram-negative infections, including multidrug-resistant (MDR) strains of Pseudomonas aeruginosa and Enterobacterales. It is particularly effective against strains producing extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases. Susceptibility testing is critical for guiding therapy, especially in patients with infections caused by resistant pathogens.

Content:

  • Testing Methods:
    • Disk Diffusion (Kirby-Bauer Method):
      • Disks containing ceftolozane-tazobactam (30/10 µg) are placed on Mueller-Hinton agar plates inoculated with the bacterial isolate.
      • After incubation, the diameter of the inhibition zone is measured and interpreted using CLSI or EUCAST guidelines.
    • Minimum Inhibitory Concentration (MIC) Testing:
      • MIC is determined using broth microdilution, agar dilution, or automated systems.
      • The MIC is the lowest concentration of ceftolozane-tazobactam that inhibits visible bacterial growth.

Application:

  • Clinical Use:
    • Ceftolozane-tazobactam is used for treating:
      • Complicated urinary tract infections (cUTIs), including pyelonephritis.
      • Complicated intra-abdominal infections (cIAIs), often in combination with metronidazole for anaerobic coverage.
      • Hospital-acquired and ventilator-associated pneumonia (HAP/VAP) caused by susceptible Gram-negative organisms.
      • Bloodstream infections (BSIs) caused by multidrug-resistant Pseudomonas aeruginosa and ESBL-producing Enterobacterales.
    • Susceptibility testing ensures its efficacy, particularly for multidrug-resistant infections.
  • Antimicrobial Stewardship:
    • Promotes the appropriate use of ceftolozane-tazobactam in resistant infections to reduce reliance on colistin or tigecycline.
    • Supports de-escalation of therapy based on susceptibility results, avoiding unnecessary exposure to broader-spectrum agents.
    • Encourages its use as an alternative to carbapenems for infections caused by ESBL-producing Enterobacterales.

Ceftolozane-tazobactam susceptibility testing is essential for managing infections caused by multidrug-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa and ESBL-producing Enterobacterales. Standardized methods, such as MIC testing and disk diffusion, ensure reliable results.

AffiBIOTICS® Ceftolozane-Tazobactam C/T 40 µg Disc
CAT# AFG-LFC-0129
Size: 50 Discs
For Price Contact info@affigen.com 0.0 USD
AffiBIOTICS® Ceftolozane-Tazobactam C/T 40 µg Disc
CAT# AFG-LFC-0128
Size: 5x50 Disc
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD